Generate a personalized week-by-week dose escalation schedule for any peptide that requires titration. Enter your starting and target doses, choose your escalation steps and start date, and get exact dates for every dose increase — from semaglutide and tirzepatide to CJC-1295/Ipamorelin and beyond.
Free to use, no signup required. Print your schedule or share it with your healthcare provider via a shareable link.
Enter your starting dose, target dose, and escalation parameters, then click “Generate Schedule” to see your personalized titration timeline.
Peptide titration is the process of starting a medication at a low dose and gradually increasing it over a defined period until the target therapeutic dose is reached. This approach is standard medical practice for many peptide therapies, particularly GLP-1 receptor agonists like semaglutide, tirzepatide, and liraglutide. The primary purpose is to give your body time to adapt to the medication, significantly reducing the incidence and severity of side effects — especially the gastrointestinal symptoms (nausea, vomiting, diarrhea) that are most common during the early weeks of treatment.
Without proper titration, jumping directly to a full therapeutic dose dramatically increases the risk of adverse effects that could lead to treatment discontinuation. Clinical trials for both semaglutide and tirzepatide demonstrated that patients who followed structured titration protocols had significantly better adherence rates and reported milder side effects compared to those who escalated too quickly.
Titration is not unique to peptide therapies — it is used across many classes of medications including antidepressants, blood pressure medications, and insulin. For peptides specifically, the escalation timeline varies by compound: weekly GLP-1 agonists typically titrate over 16–24 weeks with 4-week intervals at each dose, while growth hormone secretagogues may follow shorter 2–4 week ramp-up periods. Your healthcare provider may also personalize the schedule based on your tolerance, body weight, and treatment goals.
The standard semaglutide titration schedule for weight management (Wegovy) follows a 5-step dose escalation over 16–20 weeks: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, injected once weekly. Each dose level is maintained for 4 weeks before increasing, giving your GLP-1 receptors time to down-regulate and your gut to adapt to slowed gastric emptying.
During the first phase (0.25 mg), most patients notice mild nausea and subtle appetite changes. By the 0.5 mg phase, appetite suppression becomes more pronounced, and early weight loss typically begins. The 1.0 mg dose is where many patients report the most significant shift in food noise and cravings. At 1.7 mg and 2.4 mg, the full therapeutic effect is achieved, with clinical trials showing average weight loss of 15–17% of body weight over 68 weeks.
If GI side effects are significant at any dose level, it is common and safe to extend the time at that dose for an additional 2–4 weeks before escalating. Compounded semaglutide follows the same titration principle — the dose amounts and timing are identical, only the vial concentration and delivery mechanism differ. Use our to determine exact syringe units for compounded vials. Learn more about semaglutide in our .
Looking for a provider? Find a clinic that prescribes semaglutide →
Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist with a 6-step titration: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, injected once weekly. This longer ramp-up over 24+ weeks reflects tirzepatide's higher maximum dose and dual-agonist mechanism compared to semaglutide's single GLP-1 pathway.
Clinical trial data (SURMOUNT program) showed average weight loss of 20–26% of body weight at the highest doses — the most of any approved weight loss medication. The side effect profile is similar to semaglutide, with nausea, diarrhea, and decreased appetite being most common during dose escalation phases. Many patients find their optimal dose below the maximum (10 mg is a common stopping point), balancing efficacy against side effects.
Read our full tirzepatide guide for clinical evidence, cost comparisons, and provider options.
Retatrutide is a novel triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously — a first-in-class mechanism generating significant excitement in the obesity treatment space. Its titration schedule follows a 5-step escalation: 1 mg → 2 mg → 4 mg → 8 mg → 12 mg weekly, with notably larger dose jumps than semaglutide or tirzepatide.
Phase 2 trial data showed up to 24% body weight reduction at the highest doses over 48 weeks. The glucagon receptor activation adds metabolic benefits beyond appetite suppression, including increased energy expenditure and improved lipid metabolism. The side effect profile is comparable to other GLP-1 agonists, with GI symptoms manageable through proper titration.
Learn more in our retatrutide guide.
Liraglutide (Saxenda) is a daily GLP-1 receptor agonist with a faster 5-week titration to target dose: 0.6 mg → 1.2 mg → 1.8 mg → 2.4 mg → 3.0 mg per day. Unlike weekly injectables, liraglutide requires daily subcutaneous injection, typically at the same time each day.
The daily dosing means faster onset of action but also more consistent GI side effect exposure. Compared to semaglutide, liraglutide shows somewhat lower average weight loss (about 8% of body weight) but has a longer track record of safety data. It remains a viable option for patients who prefer a gradual daily approach or who don't tolerate weekly GLP-1 medications.
See our liraglutide guide for dosing details and clinical evidence.
CJC-1295 combined with Ipamorelin is one of the most popular growth hormone secretagogue protocols. Unlike GLP-1 agonists, this combination uses a daily injection protocol — typically 5 days on, 2 days off — with bedtime administration to align with the body's natural GH pulse pattern.
The titration is simpler: start at 100 mcg of each peptide (200 mcg total) for the first month, increase to 150 mcg each (300 mcg total) for weeks 5–8, and reach the target dose of 200 mcg each (400 mcg total) for weeks 9–12. Benefits include improved sleep quality, faster recovery, enhanced body composition, and anti-aging effects. Side effects are generally mild — water retention, tingling, and occasional headaches.
Learn more in our CJC-1295/Ipamorelin guide.
Most side effects from peptide titration are temporary and improve as your body adjusts to each new dose level. The following strategies can help minimize discomfort during dose escalation:
This titration calculator uses published clinical protocols and manufacturer guidelines to generate personalized dose escalation schedules. When you select a peptide and start date, the tool maps each protocol phase to specific calendar weeks, giving you exact date ranges for every dose change. The protocols include standard titration schedules (gradual dose increases), flat-dose protocols (no escalation), cycled protocols (periodic on/off phases), and as-needed dosing patterns.
This tool is for educational purposes only. While the protocols reflect accepted clinical practice, your healthcare provider may recommend modifications based on your individual health status, body weight, medical history, concurrent medications, and treatment response. Always work with a qualified provider when starting or adjusting peptide therapy.
Calculate exact insulin syringe units from vial size, bacteriostatic water volume, and desired dose. Includes peptide presets, cost-per-dose calculator, and shareable results.
Open toolConvert peptide doses between mg, mcg, mL, and insulin syringe units. Includes semaglutide and tirzepatide presets and a units → mg reverse calculator.
Open toolComprehensive comparison of semaglutide (Wegovy) and tirzepatide (Zepbound) side effects, including nausea rates, GI tolerability, FDA status, cost, and how to choose between them.
Explore the dosing protocols, titration schedules, and administration methods for semaglutide. Understand what to expect when starting treatment with this FDA-approved GLP-1 receptor agonist.
Explore realistic expectations and clinical outcomes for tirzepatide therapy, focusing on weight loss and factors affecting results.
Discover realistic outcomes and expectations for semaglutide therapy, a GLP-1 receptor agonist, in weight loss treatment based on clinical trials and expert insights.
Common questions about peptide titration, dose escalation schedules, and using this calculator.
Titration is gradually increasing your peptide dose over time to reach a target therapeutic dose. This minimizes side effects by allowing your body to adjust. Most GLP-1 receptor agonists like semaglutide and tirzepatide follow standardized titration protocols.
Standard semaglutide titration takes 16–20 weeks to reach the full 2.4 mg weekly dose. You start at 0.25 mg weekly for 4 weeks, then increase every 4 weeks. Some providers may extend time at each dose if side effects are significant.
Not recommended. Jumping to higher doses increases severity of GI side effects like nausea, vomiting, and diarrhea. The schedule exists to help your body adapt gradually.
Rapid escalation commonly causes severe nausea, vomiting, and diarrhea. In rare cases, it's associated with more serious GI complications. Always follow the prescribed titration schedule.
Increase when you've completed the recommended weeks at your current dose AND side effects are manageable. If you're still experiencing significant nausea, stay at your current dose for an additional 1–2 weeks.
The FDA-approved max for Wegovy is 2.4 mg weekly. Some compounding pharmacies may use different protocols, but 2.4 mg/week is the standard clinical target.
Yes. If you have persistent side effects, your provider may recommend stepping back. This is common and safe. Some patients find their optimal dose is below the maximum.
Mild nausea is common and usually improves within 1–2 weeks at each dose. Eat smaller meals, stay hydrated, avoid fatty foods, and time injections in the evening. If severe or persistent, contact your provider.
It uses published clinical protocols and manufacturer guidelines to generate a personalized schedule based on your peptide, protocol, and start date. It calculates exact dates for each dose change.
No. Retatrutide is a triple agonist with a different schedule — starts at 1 mg weekly and goes to 12 mg over 16+ weeks, with larger dose jumps than semaglutide.
Yes. The titration schedule (dose amounts and timing) is the same whether using brand-name Wegovy or compounded semaglutide. The vial concentration may differ, so use our reconstitution calculator for syringe units.
Our directory can help you find peptide therapy clinics near you with experienced providers who can create a personalized titration plan.
Not Medical Advice. The information and tools provided on MyPeptideMatch.com, including this Peptide Titration Calculator, are for educational and informational purposes only. Nothing on this website constitutes medical advice, diagnosis, or treatment recommendations.
Consult a Healthcare Provider. Always seek the advice of a qualified healthcare professional before starting, stopping, or modifying any peptide therapy, medication, or supplement regimen. Never disregard professional medical advice or delay seeking it because of information obtained from this tool.
No Doctor-Patient Relationship. Use of this calculator does not create a doctor-patient or provider-patient relationship between you and MyPeptideMatch.com or any of its contributors.
Protocol Variability. The titration schedules generated by this tool are based on commonly published clinical protocols and manufacturer guidelines. Your healthcare provider may recommend a different dosing schedule based on your individual health status, body weight, medical history, concurrent medications, and treatment response. Individual dosing should always be determined by your prescribing physician.
Research-Use Peptides. Some peptides referenced on this site may only be legally available for research purposes and may not be approved by the FDA for human use. MyPeptideMatch.com does not encourage or endorse the use of any substance in violation of applicable laws or regulations.
No Liability. MyPeptideMatch.com, its owners, contributors, and affiliates assume no responsibility or liability for any errors, omissions, or outcomes resulting from the use of this tool. Use at your own risk.
Emergency. If you are experiencing a medical emergency, call 911 or your local emergency number immediately.
MyPeptideMatch